Winton Group’s Entrada Therapeutics TRDA Stock Holding History

Winton Group’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-32,555	Closed	-$461K	–	739
2024 Q1	$461K	Buy	+32,555	New	+$460K	0.03%	480

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Winton Group's TRDA Position: Q2 2024 in Review

Winton Group sold out of Entrada Therapeutics (TRDA) in Q2 2024, closing a stake of 32,555 shares — an estimated $461K sold.

Winton Group first reported a position in TRDA in Q1 2024 and held it in 1 quarter. The position peaked at $461K in Q1 2024. 84 funds tracked by Wall St. Rank hold TRDA as of Q2 2024.

Winton Group reported no remaining Entrada Therapeutics position as of Q2 2024 after selling out during the quarter.
Winton Group sold 32,555 Entrada Therapeutics shares in Q2 2024, an estimated $461K.
Winton Group first reported a position in Entrada Therapeutics in Q1 2024 and held it in 1 quarter.
Winton Group's Entrada Therapeutics position peaked at $461K in Q1 2024.
84 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2024.

Based on Winton Group's 13F filing for Q2 2024, filed 9 Aug 2024.